Neurocrine Biosciences Aktie
132,30
EUR
+2,90
EUR
+2,24
%
155,52
USD
+1,27
USD
+0,82
%
Werbung
Neurocrine Biosciences Aktie Analyse
| 09.01.09 | Neurocrine Biosciences neutral | UBS AG | |
| 11.11.08 | Neurocrine Biosciences neutral | UBS AG | |
| 31.10.08 | Neurocrine Biosciences neutral | Piper Jaffray & Co. | |
| 04.09.08 | Neurocrine Biosciences neutral | UBS AG | |
| 14.12.07 | Neurocrine Biosciences neutral | UBS AG | |
| 11.10.07 | Neurocrine Biosciences market perform | Wachovia Sec | |
| 08.01.07 | Neurocrine Biosciences neutral | UBS | |
| 05.01.07 | Neurocrine Biosciences Neutral | UBS | |
|
Werbung
|
|||
| 26.06.06 | Neurocrine Biosciences equal weight | Lehman Brothers | |
| 23.06.06 | Neurocrine Biosciences hold | A.G. Edwards & Sons | |
| 18.05.06 | Neurocrine Biosciences equal weight | Lehman Brothers | |
| 12.01.06 | Neurocrine Biosciences market perform | Leerink Swann | |
| 08.12.05 | Neurocrine Biosciences hold | Jefferies & Co | |
| 08.12.05 | Neurocrine Biosciences Hold | Jefferies & Co | |
| 08.12.05 | Neurocrine Biosciences hold | Citigroup | |
| 02.12.05 | Neurocrine Biosciences neutral | Robert W. Baird | |
Werbung
Werbung